Investor Relations
Focus on the bottleneck of isotope supply and build a high-performance, efficient, and replicable domestically-produced radionuclide technology system.
Industry-driven demand
The demand for nuclear medicine is growing rapidly, and isotope supply has become a key limiting factor.
Core technological barriers
Independently developed high-current electron accelerators and high-power target stations, forming domestic substitution capability.
Clear business model
Cash flow can be generated in the short, medium, and long term, covering irradiation services, isotope production, and the nuclear medicine pipeline.
Market and Policy Window
The global nuclear medicine market is growing rapidly, China continues to strengthen its policies, and the independent supply of medical isotopes is entering a critical window.
- The global nuclear medicine market is expected to reach $12 billion by 2030
- The compound annual growth rate of China's nuclear medicine market from 2022 to 2027 is about 19.7%.
- The national plan supports the development of independent supply capabilities for medical isotopes
Commercialization path
Short-term
Industrial irradiation and equipment output generate basic cash flow.
Mid-term
Delivery of isotope production and research equipment, serving nuclear medicine clients.
Long-term
Developing an in-house nuclear medicine drug pipeline and CRDMO platform to become an industry leader.